Multiple Myeloma and EasyM Resource Centre.
Featured
Measurable Residual Disease and Decision-Making in Multiple Myeloma
Iain Rogers2025-02-28T09:22:26-05:00August 3rd, 2024|Case Studies|
Publications, Posters & Case Studies
Jenna Kerry2025-05-15T10:08:14-04:00
Blood-based Measurable Residual Disease Measurement by Clonotypic Mass Spectrometry is Prognostic in Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplant
Jenna Kerry2025-05-15T10:08:14-04:00May 14th, 2025|Publication|
Jenna Kerry2025-05-12T11:32:03-04:00
Opportunities and Challenges for MRD Assessment in the Clinical Management of Multiple Myeloma
Jenna Kerry2025-05-12T11:32:03-04:00May 12th, 2025|Publication|
Iain Rogers2025-03-04T10:05:19-05:00
Comparison of EasyM Clonotypic Mass Spectrometry and EuroFlow MRD in Multiple Myeloma
Iain Rogers2025-03-04T10:05:19-05:00March 3rd, 2025|Publication|